COMMON STOCK PURCHASE WARRANT To Purchase 609,756 Shares of Common Stock of GENEREX BIOTECHNOLOGY CORPORATIONGenerex Biotechnology Corp • October 31st, 2005 • Pharmaceutical preparations
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, Iroquois Capital LP (the “Holder”), is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the 181st day after the date hereof (the “Initial Exercise Date”) and on or prior to the close of business on the fifth (5th) anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from Generex Biotechnology Corporation, a Delaware corporation (the “Company”), up to 609,756 shares (the “Warrant Shares”) of Common Stock, par value $0.001 per share, of the Company (the “Common Stock”). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
COMMON STOCK PURCHASE WARRANT To Purchase 609,756 Shares of Common Stock of GENEREX BIOTECHNOLOGY CORPORATIONSecurities Purchase Agreement • October 31st, 2005 • Generex Biotechnology Corp • Pharmaceutical preparations
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, __________ (the “Holder”), is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the 181st day after the date hereof (the “Initial Exercise Date”) and on or prior to the close of business on the five anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from Generex Biotechnology Corporation, a Delaware corporation (the “Company”), up to 609,756 shares (the “Warrant Shares”) of Common Stock, par value $0.001 per share, of the Company (the “Common Stock”). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
6% SECURED CONVERTIBLE DEBENTURE DUE SEPTEMBER 16, 2006Securities Purchase Agreement • October 31st, 2005 • Generex Biotechnology Corp • Pharmaceutical preparations • New York
THIS DEBENTURE is one of a series of duly authorized and issued 6% Secured Convertible Debentures of Generex Biotechnology Company, a Delaware corporation, having a principal place of business at 33 Harbour Square, Suite 202, Toronto, Ontario Canada M5J2G2 (the “Company”), designated as its 6% Convertible Debenture, due September 16, 2006 (the “Debenture(s)”).
ADDITIONAL INVESTMENT RIGHT To Purchase $500,000 Principal Amount of 6% Convertible Debentures and Warrants Generex Biotechnology CorporationPurchase Agreement • October 31st, 2005 • Generex Biotechnology Corp • Pharmaceutical preparations
THIS ADDITIONAL INVESTMENT RIGHT (the “AIR”) certifies that, for value received, _____________ (the “Holder”), is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the 181st day following the date hereof (the “Initial Exercise Date”) and on or prior to the earlier of the close of business on the 12 month anniversary of the Effective Date and the two year anniversary of the date hereof (the “Termination Date”) but not thereafter, to subscribe for and purchase from Generex Biotechnology Corporation, a Delaware corporation (the “Company”), up to $500,000 principal amount of 6% Convertible Debentures (the “AIR Debenture”) and warrants to purchase shares of Common Stock of the Company as described herein at an exercise price of $0.82 per share (the “AIR Warrant Exercise Price”) (subject to adjustment hereunder and thereunder) (the “AIR Warrant”). Subject to the terms and conditions hereof, upon the purchase
Generex Biotechnology CorporationGenerex Biotechnology Corp • October 31st, 2005 • Pharmaceutical preparations
We make reference to the Promissory Note & Agreement (the “Note”) dated April 4, 2005 in the principal amount of One Hundred Thousand Dollars ($100,000) executed and delivered by Generex Biotechnology Corporation (the “Borrower”) in favour of Omicron Master Trust (the “Holder”), as the same was amended by letter agreement dated June 7, 2005.
Generex Biotechnology CorporationGenerex Biotechnology Corp • October 31st, 2005 • Pharmaceutical preparations
We make reference to the Promissory Note & Agreement (the “Note”) dated March 28, 2005 in the principal amount of Five Hundred Thousand Dollars ($500,000) executed and delivered by Generex Biotechnology Corporation (the “Borrower”) in favour of Cranshire Capital, L.P. (the “Holder”), as the same was amended by letter agreement dated June 7, 2005.
